Signaling pathways
-
BA8780 ALK-IN-28Summary: Anaplasticlymphomakinase (ALK) inhibitors. -
BA8781 BrigatinibSummary: Brigatinib (AP-26113) is a potent, selective, orally active inhibitor. - BA8782 MS4078Summary: MS4078 is a ligand-based mesenchymal lymphoma kinase (degradant).
- BA8783 R-268712Summary: R-268712 is an orally effective selective inhibitor.
- BA8784 IruplinalkibSummary: Iruplinalkib (WX-0593) is a potent, selective, orally active and tyrosine kinase inhibitor.
- BA8785 UNC5293Summary: UNC5293 is a selective and potent inhibitor (=190 pM).
- BA8786 TL13-112Summary: TL13-112 is an effective selective degrader.
- BA8787 CPD-1224Summary: CPD-1224 is an orally effective inhibitor and is an inhibitor derivative of the coupling ligand.
- BA8788 MS4077Summary: MS4077 is a ligand-based mesenchymal lymphoma kinase (degradant).
- BA8789 FiconalkibSummary: Ficonalkib is a potent inhibitor of the mesenchymal lymphoma kinase, ALK, a tyrosine kinase receptor.